Proxy Votes Now

Home › Funds › Franklin Alternative Strategies Fund

Franklin Alternative Strategies Fund (FAAAX) proxy voting record 2025-2026

Fund family: Franklin Alternative Strategies Funds · Filed by GEORGE PUTNAM BALANCED FUND (CIK 81259) · SEC series S000042023

Share classes and tickers: FAAAX (C000130561), FABZX (C000130565), FASCX (C000130562), FASRX (C000130564), FSKKX (C000130563)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 903 with, 25 against, 20 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 16 FOR, 11 AGAINST, 0 abstained, by the filing’s own vote-source field.

No item-level comparison with other Franklin Alternative Strategies Funds funds is possible: fewer than three other funds of the family voted in 2025-2026.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 77.6% of this fund’s 948 such votes could be given a sector; the other 212 (22.4%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care312103.2%
Utilities12664.8%
Industrials10754.7%
Consumer Discretionary5635.4%
Technology4400.0%
Finance3200.0%
Miscellaneous2200.0%
Consumer Staples1715.9%
Basic Materials1000.0%
Telecommunications1000.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5760
Audit-related950
Say-on-Pay780
Compensation602
Capital Structure570
Corporate Governance5412
Other130
Shareholder Rights and Defenses113
Other Social Issues43
Environment or Climate33

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Kymera Therapeutics, Inc.June 24, 2026$5M30
CVS Health CorporationMay 14, 2026$3M171
Edwards Lifesciences CorporationMay 7, 2026$3M120
Merck & Co., Inc.May 26, 2026$3M183
Insmed IncorporatedMay 13, 2026$2M30
Agilent Technologies, Inc.March 18, 2026$2M70
Constellation Energy CorporationApril 28, 2026$2M141
Thermo Fisher Scientific Inc.May 20, 2026$2M130

Notable votes against management

MeetingCompanyProposalFundMgmt
May 14, 2026CVS Health CorporationStockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposalForAgainst
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
April 28, 2026Constellation Energy CorporationTo consider a shareholder proposal (if properly presented) requesting a report assessing the bases for the company's diversity, equity and inclusion initiatives Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
May 21, 2026NextEra Energy, Inc.A proposal entitled "Paris Agreement Alignment" requesting NextEra Energy publish a report describing if and how the Company plans to reduce its total contribution to climate change and align its operations and investments with the Paris Agreement's goal of maintaining global temperatures well below 2 degrees Celsius, and ideally, 1.5 degrees Celsius. Shareholder proposalForAgainst
May 21, 2026NextEra Energy, Inc.A proposal entitled "Report on Net Zero Business Performance Risks" requesting the Board of Directors of NextEra Energy prepare a report within the next year, evaluating the potential costs and benefits to NextEra Energy created by aggressive emission reduction policies. Shareholder proposalAgainstFor
April 17, 2026The Boeing CompanyBoard Committee on Disability Access. Shareholder proposalAgainstFor
April 17, 2026The Boeing CompanyAction by Written Consent. Shareholder proposalForAgainst
May 20, 2026FirstEnergy Corp.Independent Board Chairman Shareholder proposalForAgainst
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor

Search this fund’s votes by company

955 ballot items at 97 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Franklin Alternative Strategies Fund (FAAAX) voted at 97 shareholder meetings of 96 companies, on 955 ballot items in all. Where management made a recommendation, the fund followed it on 95.3% of the items and voted against it 25 times. Its most frequent area of disagreement was corporate governance (12 of its votes against management). It voted on 27 shareholder proposals.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.